News|Articles|March 13, 2025

Pharma Pulse 3/13/25: Notable SCOPE 2025 Discussions, Pharmacists Play Unique Role in Clean Sports & more

The latest news for pharma industry insiders.

Notable Discussions from SCOPE 2025: Aiming to Calculate, Accommodate, and Innovate for Enhanced Drug Development

This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, and eCOA.

Pharmacists Play a Unique Role in Creating Clean Sports

A strong knowledge of pharmacology and clinical pharmacotherapeutics is essential for sports pharmacists, enabling them to support athletes' overall health while ensuring compliance with anti-doping regulations.
University of South Florida Gets $40 Million to Start Cyber and AI College

Philanthropists Arnie and Lauren Bellini donate what is the largest gift in the school’s history, hoping to turn the Tampa Bay area into ‘Cyber Bay.’

ViiV Healthcare Announces New Implementation Study Data Showing Zero Cases of HIV with Apretude

ViiV Healthcare announced new data from two implementation studies showing zero cases of HIV acquisition for Apretude, the only long-acting injectable approved for HIV prevention. Real-world data were also presented for Cabenuva, the only approved, complete long-acting injectable treatment regimen, showing its effectiveness in the three years since it has been available.

Scott Snyder on LinkedIn

Excited to share my perspectives on the transformative potential of Direct-to-patient solutions in a recent interview with Pharmaceutical Executive. We are in the early innings of DTP, but the upside for patients and pharma companies is massive. EVERSANA #digitalhealth

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.